Most Read Articles
2 days ago
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting. 
Pearl Toh, 05 Aug 2020
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.

Tbo-filgrastim more cost-effective than filgrastim for stem cell mobilization, engraftment

21 Dec 2019

Compared with filgrastim, tbo-filgrastim delivers similar efficacy and confers a cost-savings benefit for autologous peripheral blood progenitor cell (PBPC) mobilization and stem cell engraftment, results of a retrospective review have shown.

No statistically significant differences were seen on CD34+ counts during stem cell mobilization, neutrophil engraftment, infection rates during the engraftment phase, nor duration of hospitalization during the engraftment phase.

More patients in the tbo-filgrastim group were administered plerixafor per protocol, which led to more patients meeting their PBPC collection goal in 1 day with fewer collection days overall. However, institutional protocol changes could have confounded this finding.

Use of tbo-filgrastim also resulted in an average cost savings of $2,664.26 per patient ($1,907.33 for PBPC mobilization and $756.93 for stem cell engraftment) when comparing dollars spent on granulocyte colony-stimulating factor products only.

This study included 71 patients who received an autologous haematopoietic stem cell transplant (HSCT) from 1 January 2013 to 31 December 2016 with a documented administration of tbo-filgrastim or filgrastim. The authors retrospectively compared tbo-filgrastim with filgrastim in the autologous HSCT setting approximately 1 year after a system-wide formulary change to the former for all on- and off-label indications.

“Filgrastim, a granulocyte colony-stimulating factor, is commonly used in autologous HSCTs to assist with PBPC collection and to support stem cell engraftment,” the authors said. “In the United States, tbo-filgrastim is approved under its own Biologic License Application and is limited to a single indication excluding the HSCT population.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting. 
Pearl Toh, 05 Aug 2020
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.